Back to results
US 10,765,701 B2Granted
Elimination of CD19-positive lymphoid malignancies by CD19-CAR expressing NK cells
AssigneeNantKwest, Inc.
InventorsHans G. Klingemann, Laurent H. Boissel, Patrick Soon-Shiong
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions of NK-92® cells that express a CD19 CAR, CD16 and IL2, and the method of using these cells to and treat cancer in a patient.
Claims25
A recombinant isolated natural killer (NK)-92 cell expressing an anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) and a fragment crystallizable (Fc) receptor, wherein the anti-CD19 CAR has the amino acid sequence of SEQ ID NO:12, wherein the NK-92 cell has an accession number selected from the group consisting of CRL-2407, PTA 6670, CRL-2408, CRL-2409, PTA-6967, PTA-8837 and PTA-8836.
Dependencies are inferred from the claim text.